Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.

Name: Αlpha¹ Rigor Record — Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
Item: Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
Rating: 59
Author: Αlpha¹

He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 3 high issues for “Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized trial with rigorous design, clear reporting of methods and results, and appropriate statistical analysis. The main weaknesses are a vague ethics statement (no named committee or protocol number) and a vague data availability statement, both of which are fixable reporting gaps. Minor copyedit issues and a small internal inconsistency in Table 2 warrant attention.

Both reviewers classified the study as interventional, which is adopted. The evaluation covered the full text, with verification components checking citations (34 references, none retracted or missing), statistics (6 tests recomputed consistently), reproducibility (4 links live), and preregistration (ClinicalTrials.gov). The integrity check flagged a minor arithmetic inconsistency in Table 2 (sum of distant metastasis subtypes exceeds total).

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 4 recomputed directly from the reported test statistics, 2 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites prior research on multigene signatures (Oncotype DX, Mammaprint, HER2DX) and notes the lack of triple negative breast cancer-specific signatures validated prospectively. It also references the authors' previous development of the integrated mRNA-lncRNA signature and preliminary data suggesting high-risk patients derive less benefit from taxane-based chemotherapy. The hypothesis logically follows from this evidence, linking the signature to the addition of gemcitabine and cisplatin. Limitations of prior research are acknowledged (e.g., 'signatures specific to triple negative breast cancer are scarce and lack validation in prospective clinical trials').

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on multigene signatures and the need for improved adjuvant therapy in triple negative breast cancer, and it provides a logical rationale for the study hypothesis.

Evidence

paraphrase[Introduction, paragraph 2]

“In our previous research, we developed an integrated mRNA-lncRNA signature (three mRNAs: FCGR1A, RSAD2, and CHRDL1; two lncRNAs: HIF1A-AS2 and AK124454) that could effectively classify patients with triple negative breast cancer into groups at high risk or low risk for disease recurrence.”

direct quote[Introduction, paragraph 3]

“Given the strong pre-clinical evidence for a synergistic effect of cisplatin with gemcitabine, and the high objective response rate observed with this doublet as first line treatment in a phase 3 trial of metastatic triple negative breast cancer, we hypothesised that patients with high risk, early stage triple negative breast cancer identified using the multigene signature would benefit from the addition of gemcitabine and cisplatin to the standard anthracycline/taxane based regimen in the adjuvant setting.”